Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA – Results of an international collaborative study

Vaccine ◽  
2017 ◽  
Vol 35 (6) ◽  
pp. 966-971 ◽  
Author(s):  
Sylvie Morgeaux ◽  
Bertrand Poirier ◽  
C. Ian Ragan ◽  
Dianna Wilkinson ◽  
Ulrich Arabin ◽  
...  
Keyword(s):  
Collaborative Study ◽  
Rabies Vaccine ◽  
Human Rabies ◽  
Vaccine Potency ◽  
International Collaborative ◽  
International Collaborative Study

SFTG international collaborative study on in vitro micronucleus test

2006 ◽  
Vol 607 (1) ◽  
pp. 37-60 ◽  
Author(s):  
M. Gillian Clare ◽  
Giocondo Lorenzon ◽  
Leslie C. Akhurst ◽  
Daniel Marzin ◽  
Joost van Delft ◽  
...  
Keyword(s):  
Micronucleus Test ◽  
Collaborative Study ◽  
International Collaborative ◽  
International Collaborative Study

scholarly journals Assessing Rabies Vaccine Protection against a Novel Lyssavirus, Kotalahti Bat Lyssavirus

Viruses ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 947
Author(s):  
Rebecca Shipley ◽  
Edward Wright ◽  
Fabian Z. X. Lean ◽  
David Selden ◽  
Daniel L. Horton ◽  
...  
Keyword(s):  
Recombinant Virus ◽  
Protective Immunity ◽  
Rabies Vaccine ◽  
Human Rabies ◽  
The Novel ◽  
Vaccine Protection ◽  
Full Length Genome ◽  
Prototype Virus

Rabies is a fatal encephalitis caused by an important group of viruses within the Lyssavirus genus. The prototype virus, rabies virus, is still the most commonly reported lyssavirus and causes approximately 59,000 human fatalities annually. The human and animal burden of the other lyssavirus species is undefined. The original reports for the novel lyssavirus, Kotalahti bat lyssavirus (KBLV), were based on the detection of viral RNA alone. In this report we describe the successful generation of a live recombinant virus, cSN-KBLV; where the full-length genome clone of RABV vaccine strain, SAD-B19, was constructed with the glycoprotein of KBLV. Subsequent in vitro characterisation of cSN-KBLV is described here. In addition, the ability of a human rabies vaccine to confer protective immunity in vivo following challenge with this recombinant virus was assessed. Naïve or vaccinated mice were infected intracerebrally with a dose of 100 focus-forming units/30 µL of cSN-KBLV; all naïve mice and 8% (n = 1/12) of the vaccinated mice succumbed to the challenge, whilst 92% (n = 11/12) of the vaccinated mice survived to the end of the experiment. This report provides strong evidence for cross-neutralisation and cross-protection of cSN-KBLV using purified Vero cell rabies vaccine.

SFTG international collaborative study on in vitro micronucleus test

2006 ◽  
Vol 607 (1) ◽  
pp. 13-36 ◽  
Author(s):  
Elisabeth Lorge ◽  
Veronique Thybaud ◽  
Marilyn J. Aardema ◽  
Jo Oliver ◽  
Akihiro Wakata ◽  
...  
Keyword(s):  
Micronucleus Test ◽  
Collaborative Study ◽  
International Collaborative ◽  
International Collaborative Study

SFTG international collaborative study on in vitro micronucleus test

2006 ◽  
Vol 607 (1) ◽  
pp. 125-152 ◽  
Author(s):  
Jo Oliver ◽  
Jean-Roch Meunier ◽  
Takumi Awogi ◽  
Azeddine Elhajouji ◽  
Marie-Claude Ouldelhkim ◽  
...  
Keyword(s):  
Micronucleus Test ◽  
Collaborative Study ◽  
International Collaborative ◽  
International Collaborative Study
Sign in / Sign up

Export Citation Format

Share Document